| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 271 | 2024 | 3613 | 19.080 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 69 | 2024 | 495 | 8.940 |
Why?
|
| Myelodysplastic Syndromes | 79 | 2024 | 1394 | 5.950 |
Why?
|
| Staurosporine | 30 | 2022 | 242 | 5.010 |
Why?
|
| Cytarabine | 60 | 2024 | 697 | 3.970 |
Why?
|
| Leukemia, Myeloid | 42 | 2020 | 694 | 3.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 105 | 2024 | 11742 | 3.520 |
Why?
|
| Remission Induction | 96 | 2024 | 2396 | 3.290 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 30 | 2024 | 1551 | 2.730 |
Why?
|
| Leukemia | 32 | 2024 | 1522 | 2.690 |
Why?
|
| Antineoplastic Agents | 97 | 2024 | 13639 | 2.680 |
Why?
|
| Mutation | 112 | 2024 | 30052 | 2.310 |
Why?
|
| Protein Kinase Inhibitors | 43 | 2023 | 5671 | 2.070 |
Why?
|
| Azacitidine | 20 | 2024 | 336 | 2.000 |
Why?
|
| Leukemia, Promyelocytic, Acute | 19 | 2022 | 251 | 1.930 |
Why?
|
| Isocitrate Dehydrogenase | 19 | 2024 | 938 | 1.790 |
Why?
|
| Enzyme Inhibitors | 24 | 2022 | 3712 | 1.620 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 20 | 2013 | 686 | 1.430 |
Why?
|
| Myeloproliferative Disorders | 16 | 2023 | 613 | 1.400 |
Why?
|
| Antimetabolites, Antineoplastic | 14 | 2018 | 646 | 1.320 |
Why?
|
| Sulfonamides | 20 | 2024 | 1978 | 1.280 |
Why?
|
| Hematologic Neoplasms | 17 | 2023 | 1896 | 1.280 |
Why?
|
| Prognosis | 112 | 2024 | 29625 | 1.230 |
Why?
|
| Humans | 568 | 2024 | 761504 | 1.170 |
Why?
|
| Daunorubicin | 19 | 2024 | 156 | 1.170 |
Why?
|
| Pyrimidines | 32 | 2019 | 3028 | 1.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 42 | 2024 | 5671 | 1.160 |
Why?
|
| Triazines | 7 | 2021 | 311 | 1.150 |
Why?
|
| Leukemia, Hairy Cell | 5 | 2023 | 82 | 1.140 |
Why?
|
| Disease-Free Survival | 56 | 2024 | 6814 | 1.120 |
Why?
|
| Aminopyridines | 9 | 2021 | 573 | 1.120 |
Why?
|
| Asparaginase | 6 | 2024 | 240 | 1.100 |
Why?
|
| Piperazines | 27 | 2021 | 2523 | 1.070 |
Why?
|
| Transplantation, Homologous | 30 | 2024 | 4806 | 1.070 |
Why?
|
| Aged | 239 | 2024 | 169289 | 1.020 |
Why?
|
| Stem Cell Transplantation | 17 | 2022 | 1600 | 0.990 |
Why?
|
| Glycine | 5 | 2021 | 663 | 0.980 |
Why?
|
| Acute Disease | 44 | 2023 | 7237 | 0.970 |
Why?
|
| Drug Resistance, Neoplasm | 29 | 2023 | 5305 | 0.960 |
Why?
|
| Ambulances | 2 | 2023 | 91 | 0.950 |
Why?
|
| Blast Crisis | 7 | 2017 | 102 | 0.910 |
Why?
|
| Hematology | 5 | 2023 | 243 | 0.900 |
Why?
|
| Aminoglycosides | 5 | 2018 | 160 | 0.880 |
Why?
|
| Triazoles | 7 | 2017 | 903 | 0.880 |
Why?
|
| Neoplasm, Residual | 8 | 2024 | 1008 | 0.870 |
Why?
|
| Gene Expression Regulation, Leukemic | 16 | 2016 | 651 | 0.850 |
Why?
|
| Nuclear Proteins | 22 | 2024 | 5796 | 0.840 |
Why?
|
| Middle Aged | 241 | 2024 | 220895 | 0.830 |
Why?
|
| Tretinoin | 10 | 2019 | 519 | 0.820 |
Why?
|
| Cytogenetics | 16 | 2022 | 198 | 0.810 |
Why?
|
| Protein-Tyrosine Kinases | 19 | 2022 | 2425 | 0.790 |
Why?
|
| Survival Rate | 54 | 2024 | 12725 | 0.790 |
Why?
|
| Aged, 80 and over | 114 | 2024 | 58976 | 0.780 |
Why?
|
| Nuclear Fission | 1 | 2021 | 3 | 0.780 |
Why?
|
| Nuclear Reactors | 1 | 2021 | 8 | 0.770 |
Why?
|
| Hydrazines | 4 | 2017 | 224 | 0.770 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2021 | 15 | 0.760 |
Why?
|
| Geriatric Assessment | 9 | 2024 | 1410 | 0.760 |
Why?
|
| Thalidomide | 10 | 2017 | 885 | 0.760 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 226 | 0.750 |
Why?
|
| Police | 1 | 2023 | 157 | 0.740 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 9 | 2024 | 1405 | 0.720 |
Why?
|
| Treatment Outcome | 107 | 2024 | 64680 | 0.720 |
Why?
|
| Tandem Repeat Sequences | 8 | 2021 | 180 | 0.710 |
Why?
|
| Proto-Oncogene Proteins | 18 | 2023 | 4511 | 0.710 |
Why?
|
| Chromosome Aberrations | 14 | 2022 | 1768 | 0.710 |
Why?
|
| Pyridines | 9 | 2023 | 2875 | 0.700 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 | 2024 | 1640 | 0.690 |
Why?
|
| Mucin-1 | 7 | 2016 | 540 | 0.690 |
Why?
|
| Adult | 206 | 2024 | 221177 | 0.690 |
Why?
|
| Philadelphia Chromosome | 6 | 2022 | 117 | 0.690 |
Why?
|
| Chemical Warfare Agents | 1 | 2019 | 19 | 0.680 |
Why?
|
| Male | 258 | 2024 | 360804 | 0.680 |
Why?
|
| Nuclear Physics | 6 | 2014 | 75 | 0.660 |
Why?
|
| Karyotyping | 16 | 2020 | 1171 | 0.660 |
Why?
|
| Female | 256 | 2024 | 392644 | 0.650 |
Why?
|
| Fusion Proteins, bcr-abl | 18 | 2016 | 431 | 0.650 |
Why?
|
| Antibodies, Bispecific | 3 | 2024 | 196 | 0.630 |
Why?
|
| Neoplasms, Second Primary | 6 | 2024 | 1052 | 0.610 |
Why?
|
| Janus Kinase 2 | 9 | 2021 | 560 | 0.610 |
Why?
|
| Blood Donors | 2 | 2020 | 345 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 8 | 9 | 2019 | 452 | 0.600 |
Why?
|
| Bone Marrow | 20 | 2023 | 2911 | 0.600 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 4 | 2016 | 37 | 0.590 |
Why?
|
| Drug Administration Schedule | 19 | 2020 | 4853 | 0.580 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2019 | 148 | 0.580 |
Why?
|
| Survival Analysis | 39 | 2024 | 10090 | 0.580 |
Why?
|
| Mastocytosis, Systemic | 2 | 2018 | 103 | 0.560 |
Why?
|
| Drug Discovery | 4 | 2018 | 1051 | 0.560 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2017 | 32 | 0.560 |
Why?
|
| Clinical Trials as Topic | 25 | 2024 | 8002 | 0.550 |
Why?
|
| Translocation, Genetic | 14 | 2020 | 1393 | 0.550 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2023 | 2803 | 0.540 |
Why?
|
| Piperidines | 11 | 2024 | 1656 | 0.520 |
Why?
|
| Adenine | 8 | 2024 | 987 | 0.500 |
Why?
|
| Gene Expression Profiling | 22 | 2024 | 9420 | 0.490 |
Why?
|
| Apoptosis | 31 | 2021 | 9486 | 0.480 |
Why?
|
| Iron Chelating Agents | 4 | 2009 | 141 | 0.470 |
Why?
|
| Disease Management | 9 | 2020 | 2508 | 0.470 |
Why?
|
| Young Adult | 59 | 2024 | 59243 | 0.470 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2009 | 891 | 0.470 |
Why?
|
| Anthracyclines | 7 | 2023 | 284 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 9280 | 0.470 |
Why?
|
| Fever of Unknown Origin | 1 | 2014 | 94 | 0.460 |
Why?
|
| Molecular Targeted Therapy | 11 | 2024 | 2811 | 0.460 |
Why?
|
| Recurrence | 31 | 2024 | 8465 | 0.460 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2017 | 629 | 0.460 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2023 | 305 | 0.460 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 8 | 2022 | 1626 | 0.450 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2014 | 99 | 0.450 |
Why?
|
| Bone Marrow Transplantation | 17 | 2014 | 2693 | 0.450 |
Why?
|
| Elementary Particles | 4 | 2014 | 52 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2016 | 2455 | 0.440 |
Why?
|
| Thiazoles | 6 | 2015 | 1517 | 0.440 |
Why?
|
| Trisomy | 5 | 2019 | 260 | 0.440 |
Why?
|
| Age Factors | 31 | 2024 | 18395 | 0.430 |
Why?
|
| Chelation Therapy | 3 | 2009 | 77 | 0.430 |
Why?
|
| Iron Overload | 4 | 2009 | 239 | 0.430 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2023 | 682 | 0.420 |
Why?
|
| Benzimidazoles | 5 | 2024 | 858 | 0.420 |
Why?
|
| Tumor Cells, Cultured | 22 | 2021 | 6132 | 0.420 |
Why?
|
| Queensland | 2 | 2023 | 52 | 0.410 |
Why?
|
| Arsenicals | 4 | 2010 | 118 | 0.410 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 4 | 2022 | 92 | 0.410 |
Why?
|
| Genomics | 11 | 2022 | 5821 | 0.410 |
Why?
|
| Immunocompromised Host | 2 | 2015 | 856 | 0.410 |
Why?
|
| Cell Proliferation | 30 | 2021 | 10445 | 0.400 |
Why?
|
| DNA Methylation | 11 | 2024 | 4398 | 0.400 |
Why?
|
| Combined Modality Therapy | 21 | 2022 | 8529 | 0.390 |
Why?
|
| Phenylurea Compounds | 7 | 2020 | 529 | 0.390 |
Why?
|
| Polycythemia Vera | 4 | 2021 | 161 | 0.380 |
Why?
|
| Thrombocythemia, Essential | 3 | 2021 | 113 | 0.380 |
Why?
|
| Dendritic Cells | 8 | 2023 | 2747 | 0.380 |
Why?
|
| Oxides | 4 | 2010 | 401 | 0.370 |
Why?
|
| Cytogenetic Analysis | 14 | 2021 | 270 | 0.370 |
Why?
|
| Protein Kinase C | 10 | 2008 | 1202 | 0.370 |
Why?
|
| Cell Line, Tumor | 37 | 2023 | 16981 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-kit | 5 | 2019 | 727 | 0.370 |
Why?
|
| Idarubicin | 7 | 2023 | 59 | 0.370 |
Why?
|
| Salvage Therapy | 9 | 2022 | 1264 | 0.370 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 319 | 0.360 |
Why?
|
| Sweet Syndrome | 3 | 2016 | 58 | 0.360 |
Why?
|
| Blood Transfusion | 7 | 2020 | 1298 | 0.360 |
Why?
|
| Interleukin-3 | 4 | 2005 | 425 | 0.360 |
Why?
|
| Primary Myelofibrosis | 3 | 2021 | 209 | 0.360 |
Why?
|
| Cell Cycle | 8 | 2015 | 2932 | 0.360 |
Why?
|
| Oleanolic Acid | 1 | 2010 | 43 | 0.350 |
Why?
|
| Immunophenotyping | 10 | 2023 | 1870 | 0.350 |
Why?
|
| Immunotherapy | 11 | 2021 | 4652 | 0.350 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2014 | 2825 | 0.350 |
Why?
|
| Refraction, Ocular | 1 | 2011 | 184 | 0.350 |
Why?
|
| Karyopherins | 3 | 2016 | 132 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 21 | 4 | 2019 | 228 | 0.340 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2024 | 2917 | 0.340 |
Why?
|
| Benzamides | 22 | 2015 | 1370 | 0.340 |
Why?
|
| Cell Differentiation | 29 | 2021 | 11528 | 0.340 |
Why?
|
| Adolescent | 65 | 2024 | 88319 | 0.340 |
Why?
|
| Treatment Failure | 6 | 2016 | 2645 | 0.340 |
Why?
|
| Lymphoma | 6 | 2023 | 1901 | 0.340 |
Why?
|
| Quinazolines | 3 | 2013 | 1371 | 0.340 |
Why?
|
| Refractive Errors | 1 | 2011 | 147 | 0.340 |
Why?
|
| Mutant Proteins | 5 | 2019 | 491 | 0.330 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 382 | 0.330 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 718 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2021 | 10766 | 0.330 |
Why?
|
| Hospitalization | 5 | 2023 | 10723 | 0.330 |
Why?
|
| Transplantation Conditioning | 9 | 2024 | 1590 | 0.320 |
Why?
|
| T-Lymphocytes | 15 | 2023 | 10194 | 0.320 |
Why?
|
| Core Binding Factors | 3 | 2022 | 29 | 0.320 |
Why?
|
| Anemia | 6 | 2021 | 1509 | 0.320 |
Why?
|
| Infusions, Intravenous | 8 | 2015 | 2219 | 0.320 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2009 | 286 | 0.310 |
Why?
|
| Caspases | 1 | 2011 | 879 | 0.310 |
Why?
|
| Models, Theoretical | 7 | 2020 | 3575 | 0.300 |
Why?
|
| Autoimmunity | 1 | 2016 | 1356 | 0.300 |
Why?
|
| Drug Synergism | 12 | 2020 | 1755 | 0.300 |
Why?
|
| Neutrons | 2 | 2021 | 77 | 0.300 |
Why?
|
| Chromosome Deletion | 8 | 2016 | 1386 | 0.300 |
Why?
|
| Benzoates | 1 | 2009 | 212 | 0.300 |
Why?
|
| DNA Mutational Analysis | 13 | 2019 | 4111 | 0.300 |
Why?
|
| Nucleosides | 1 | 2008 | 131 | 0.300 |
Why?
|
| Granulocyte Precursor Cells | 3 | 2012 | 49 | 0.300 |
Why?
|
| Mental Health | 2 | 2021 | 3250 | 0.300 |
Why?
|
| Neutropenia | 5 | 2017 | 885 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 13 | 6 | 2019 | 192 | 0.290 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2014 | 832 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2024 | 6484 | 0.290 |
Why?
|
| Follow-Up Studies | 37 | 2024 | 39106 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 5 | 6 | 2009 | 386 | 0.280 |
Why?
|
| Cancer Vaccines | 5 | 2021 | 1051 | 0.280 |
Why?
|
| Review Literature as Topic | 2 | 2023 | 348 | 0.280 |
Why?
|
| Bone Marrow Cells | 8 | 2021 | 2416 | 0.280 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2015 | 1914 | 0.270 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2017 | 1374 | 0.270 |
Why?
|
| Optic Nerve Diseases | 1 | 2010 | 342 | 0.270 |
Why?
|
| Hypereosinophilic Syndrome | 2 | 2004 | 97 | 0.270 |
Why?
|
| Enzyme Activation | 14 | 2013 | 3597 | 0.270 |
Why?
|
| Methotrexate | 8 | 2022 | 1719 | 0.270 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2016 | 857 | 0.260 |
Why?
|
| Mitoxantrone | 8 | 2019 | 148 | 0.260 |
Why?
|
| Thrombosis | 2 | 2018 | 2942 | 0.260 |
Why?
|
| Mice | 53 | 2023 | 81525 | 0.260 |
Why?
|
| Animals | 75 | 2023 | 168459 | 0.260 |
Why?
|
| Choroid | 1 | 2008 | 360 | 0.260 |
Why?
|
| Tetradecanoylphorbol Acetate | 9 | 1999 | 817 | 0.260 |
Why?
|
| Optic Disk | 1 | 2010 | 421 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 8547 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 12 | 2016 | 3602 | 0.250 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 455 | 0.250 |
Why?
|
| Pyrazoles | 5 | 2019 | 2009 | 0.250 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2005 | 55 | 0.250 |
Why?
|
| Thrombocytopenia | 9 | 2020 | 1181 | 0.250 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2008 | 251 | 0.250 |
Why?
|
| Neoplasms | 14 | 2022 | 22170 | 0.250 |
Why?
|
| Vincristine | 4 | 2016 | 1036 | 0.240 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 2006 | 178 | 0.240 |
Why?
|
| Dioxygenases | 4 | 2022 | 345 | 0.240 |
Why?
|
| Gene Duplication | 2 | 2020 | 314 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2019 | 410 | 0.240 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2015 | 61 | 0.240 |
Why?
|
| Mitochondria | 6 | 2019 | 3624 | 0.230 |
Why?
|
| Glutarates | 2 | 2018 | 243 | 0.230 |
Why?
|
| Eosinophilia | 2 | 2022 | 560 | 0.230 |
Why?
|
| Small Molecule Libraries | 2 | 2021 | 733 | 0.230 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 823 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 10 | 2022 | 3396 | 0.220 |
Why?
|
| Anxiety | 3 | 2023 | 4573 | 0.220 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2020 | 774 | 0.220 |
Why?
|
| Etoposide | 9 | 2019 | 634 | 0.220 |
Why?
|
| Flow Cytometry | 10 | 2017 | 5869 | 0.220 |
Why?
|
| Elementary Particle Interactions | 2 | 2013 | 17 | 0.220 |
Why?
|
| Myeloid Cells | 5 | 2015 | 823 | 0.220 |
Why?
|
| Vidarabine | 5 | 2021 | 336 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 10 | 2022 | 7390 | 0.220 |
Why?
|
| Maximum Tolerated Dose | 7 | 2017 | 883 | 0.220 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2018 | 411 | 0.220 |
Why?
|
| Signal Transduction | 20 | 2023 | 23445 | 0.220 |
Why?
|
| Pyrazines | 6 | 2020 | 1201 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 14 | 2015 | 4575 | 0.220 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 484 | 0.210 |
Why?
|
| Myopia | 2 | 2003 | 253 | 0.210 |
Why?
|
| Proto-Oncogenes | 5 | 2017 | 321 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2015 | 2872 | 0.210 |
Why?
|
| Polymerase Chain Reaction | 8 | 2017 | 6075 | 0.210 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2004 | 200 | 0.210 |
Why?
|
| Phosphorylation | 14 | 2021 | 8320 | 0.210 |
Why?
|
| Transplantation, Autologous | 10 | 2011 | 2115 | 0.210 |
Why?
|
| Epigenesis, Genetic | 4 | 2022 | 3802 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 2 | 2020 | 120 | 0.210 |
Why?
|
| Retrospective Studies | 40 | 2024 | 80636 | 0.210 |
Why?
|
| Internet | 4 | 2020 | 3092 | 0.210 |
Why?
|
| Drug Screening Assays, Antitumor | 8 | 2019 | 718 | 0.200 |
Why?
|
| Isoquinolines | 4 | 2016 | 352 | 0.200 |
Why?
|
| Monocytes | 9 | 1999 | 2570 | 0.200 |
Why?
|
| Ovarian Neoplasms | 2 | 2018 | 4876 | 0.200 |
Why?
|
| Iron | 2 | 2016 | 1793 | 0.200 |
Why?
|
| United States | 22 | 2023 | 72334 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 6 | 2016 | 1347 | 0.200 |
Why?
|
| Erythropoiesis | 2 | 2021 | 683 | 0.200 |
Why?
|
| Prospective Studies | 28 | 2023 | 54425 | 0.200 |
Why?
|
| United States Food and Drug Administration | 4 | 2018 | 1664 | 0.200 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2022 | 186 | 0.190 |
Why?
|
| Aniline Compounds | 4 | 2020 | 1069 | 0.190 |
Why?
|
| Arabinonucleosides | 2 | 2014 | 34 | 0.190 |
Why?
|
| MicroRNAs | 7 | 2015 | 3816 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 1943 | 0.190 |
Why?
|
| Pyrrolidines | 2 | 2015 | 338 | 0.190 |
Why?
|
| Lactones | 3 | 1997 | 317 | 0.190 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2024 | 727 | 0.190 |
Why?
|
| Erythropoietin | 3 | 2009 | 719 | 0.190 |
Why?
|
| Cancer Care Facilities | 1 | 2024 | 422 | 0.190 |
Why?
|
| Dark Adaptation | 1 | 2002 | 222 | 0.190 |
Why?
|
| Jacobsen Distal 11q Deletion Syndrome | 1 | 2020 | 2 | 0.190 |
Why?
|
| Oncogenes | 1 | 2007 | 1222 | 0.190 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2017 | 359 | 0.190 |
Why?
|
| Hydroxamic Acids | 3 | 2020 | 481 | 0.180 |
Why?
|
| Antigens, Neoplasm | 6 | 2021 | 1993 | 0.180 |
Why?
|
| Risk Factors | 32 | 2024 | 74206 | 0.180 |
Why?
|
| Algorithms | 7 | 2022 | 14031 | 0.180 |
Why?
|
| Cytoplasm | 2 | 2018 | 1510 | 0.180 |
Why?
|
| Ukraine | 1 | 2021 | 149 | 0.180 |
Why?
|
| U937 Cells | 7 | 2019 | 261 | 0.180 |
Why?
|
| Cyclophosphamide | 8 | 2022 | 2218 | 0.180 |
Why?
|
| Graft vs Host Disease | 9 | 2024 | 3029 | 0.180 |
Why?
|
| DNA-Binding Proteins | 13 | 2024 | 9606 | 0.180 |
Why?
|
| Circadian Rhythm | 2 | 2011 | 2576 | 0.180 |
Why?
|
| Leukemia, B-Cell | 2 | 2016 | 84 | 0.180 |
Why?
|
| Alternative Splicing | 4 | 2014 | 1093 | 0.180 |
Why?
|
| Stem Cells | 4 | 2019 | 3522 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
| Cell Cycle Proteins | 4 | 2024 | 3448 | 0.180 |
Why?
|
| Retina | 1 | 2011 | 2659 | 0.180 |
Why?
|
| Peptides | 4 | 2013 | 4358 | 0.180 |
Why?
|
| Glaucoma | 1 | 2010 | 1185 | 0.180 |
Why?
|
| Active Transport, Cell Nucleus | 3 | 2017 | 435 | 0.170 |
Why?
|
| Blotting, Western | 9 | 2017 | 5035 | 0.170 |
Why?
|
| STAT5 Transcription Factor | 4 | 2015 | 265 | 0.170 |
Why?
|
| Drug Therapy, Combination | 8 | 2020 | 6310 | 0.170 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 412 | 0.170 |
Why?
|
| Azepines | 2 | 2019 | 329 | 0.170 |
Why?
|
| Recombinant Proteins | 8 | 2009 | 6534 | 0.170 |
Why?
|
| Receptors, Interleukin | 1 | 2021 | 243 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2015 | 1606 | 0.170 |
Why?
|
| Patient Selection | 4 | 2020 | 4244 | 0.170 |
Why?
|
| Dog Diseases | 1 | 2020 | 141 | 0.170 |
Why?
|
| Democratic People's Republic of Korea | 1 | 2019 | 12 | 0.170 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2019 | 13 | 0.170 |
Why?
|
| Phenotype | 8 | 2020 | 16591 | 0.170 |
Why?
|
| Cell Survival | 10 | 2017 | 5791 | 0.170 |
Why?
|
| Quinolones | 3 | 2007 | 378 | 0.170 |
Why?
|
| Uniparental Disomy | 1 | 2019 | 45 | 0.170 |
Why?
|
| Venous Thromboembolism | 2 | 2024 | 1866 | 0.170 |
Why?
|
| Dexamethasone | 6 | 2021 | 1948 | 0.170 |
Why?
|
| Medical Oncology | 5 | 2023 | 2321 | 0.160 |
Why?
|
| Erythroid Cells | 1 | 2021 | 238 | 0.160 |
Why?
|
| Australia | 1 | 2023 | 1250 | 0.160 |
Why?
|
| Farnesyltranstransferase | 3 | 2007 | 71 | 0.160 |
Why?
|
| Angiotensin I | 1 | 2019 | 56 | 0.160 |
Why?
|
| Eye | 1 | 2003 | 712 | 0.160 |
Why?
|
| Hematinics | 3 | 2017 | 282 | 0.160 |
Why?
|
| Drug Design | 3 | 2020 | 1048 | 0.160 |
Why?
|
| Hospitals | 2 | 2023 | 3882 | 0.160 |
Why?
|
| Skin Neoplasms | 4 | 2023 | 5821 | 0.160 |
Why?
|
| Metabolomics | 3 | 2018 | 1659 | 0.160 |
Why?
|
| bcl-X Protein | 2 | 2014 | 410 | 0.160 |
Why?
|
| Mycoses | 1 | 2022 | 386 | 0.160 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2018 | 38 | 0.160 |
Why?
|
| Mutagenesis, Insertional | 1 | 2021 | 656 | 0.160 |
Why?
|
| Urate Oxidase | 1 | 2018 | 31 | 0.160 |
Why?
|
| Quinazolinones | 1 | 2020 | 221 | 0.150 |
Why?
|
| Gene Frequency | 4 | 2019 | 3606 | 0.150 |
Why?
|
| Polyethylene Glycols | 2 | 2023 | 1189 | 0.150 |
Why?
|
| Receptors, IgG | 1 | 2021 | 559 | 0.150 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 2226 | 0.150 |
Why?
|
| Thrombopoietin | 1 | 2000 | 226 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2004 | 1784 | 0.150 |
Why?
|
| Chromosomes, Human | 2 | 2019 | 441 | 0.150 |
Why?
|
| Prednisone | 4 | 2023 | 1563 | 0.150 |
Why?
|
| Leukocytosis | 2 | 2018 | 251 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 8 | 2020 | 6216 | 0.150 |
Why?
|
| Glutathione | 2 | 2007 | 583 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 2023 | 532 | 0.150 |
Why?
|
| Phosphoproteins | 3 | 2024 | 2448 | 0.150 |
Why?
|
| Hemoglobins | 3 | 2020 | 1525 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2016 | 140 | 0.150 |
Why?
|
| Antifungal Agents | 3 | 2022 | 752 | 0.140 |
Why?
|
| Mice, Inbred NOD | 7 | 2017 | 1827 | 0.140 |
Why?
|
| Disease Progression | 10 | 2022 | 13506 | 0.140 |
Why?
|
| RNA, Small Interfering | 7 | 2017 | 3429 | 0.140 |
Why?
|
| Cell Nucleus | 3 | 2017 | 2909 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2022 | 17904 | 0.140 |
Why?
|
| Busulfan | 3 | 2021 | 258 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2019 | 662 | 0.140 |
Why?
|
| Time Factors | 21 | 2016 | 39967 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2017 | 225 | 0.140 |
Why?
|
| Mesons | 2 | 2014 | 31 | 0.140 |
Why?
|
| Risk Assessment | 9 | 2023 | 23995 | 0.140 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2016 | 17 | 0.140 |
Why?
|
| Cyclin D2 | 1 | 2016 | 98 | 0.140 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 190 | 0.140 |
Why?
|
| RNA, Messenger | 17 | 2015 | 12795 | 0.140 |
Why?
|
| Methenyltetrahydrofolate Cyclohydrolase | 1 | 2016 | 10 | 0.140 |
Why?
|
| Lymphocyte Activation | 4 | 2010 | 5486 | 0.140 |
Why?
|
| Atovaquone | 1 | 2016 | 56 | 0.140 |
Why?
|
| Gout Suppressants | 1 | 2018 | 177 | 0.140 |
Why?
|
| Administration, Oral | 9 | 2021 | 4021 | 0.140 |
Why?
|
| Breast Neoplasms | 4 | 2018 | 21012 | 0.140 |
Why?
|
| Neoplasm Proteins | 8 | 2017 | 3617 | 0.140 |
Why?
|
| Transcription Factors | 9 | 2023 | 12128 | 0.140 |
Why?
|
| HL-60 Cells | 6 | 2016 | 363 | 0.140 |
Why?
|
| Peptide Fragments | 4 | 2019 | 5112 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2021 | 10209 | 0.130 |
Why?
|
| Quality of Life | 11 | 2023 | 13367 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 368 | 0.130 |
Why?
|
| Uric Acid | 2 | 2022 | 807 | 0.130 |
Why?
|
| Logistic Models | 9 | 2023 | 13255 | 0.130 |
Why?
|
| Alleles | 7 | 2020 | 6863 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 4016 | 0.130 |
Why?
|
| Hand Strength | 1 | 2019 | 456 | 0.130 |
Why?
|
| Multiple Myeloma | 4 | 2022 | 5146 | 0.130 |
Why?
|
| Benzothiazoles | 4 | 2020 | 247 | 0.130 |
Why?
|
| Interleukins | 1 | 2021 | 782 | 0.130 |
Why?
|
| Chromosome Inversion | 2 | 2015 | 120 | 0.130 |
Why?
|
| Inflammation | 5 | 2024 | 10773 | 0.130 |
Why?
|
| Lymphatic Diseases | 2 | 2015 | 320 | 0.130 |
Why?
|
| Chondrocalcinosis | 1 | 2017 | 84 | 0.130 |
Why?
|
| Interferometry | 2 | 2008 | 100 | 0.130 |
Why?
|
| Ferritins | 2 | 2009 | 598 | 0.130 |
Why?
|
| Blood Component Transfusion | 1 | 2016 | 142 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2020 | 2865 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2016 | 1171 | 0.130 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 246 | 0.130 |
Why?
|
| Exanthema | 3 | 2015 | 503 | 0.130 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2017 | 155 | 0.130 |
Why?
|
| Carrier Proteins | 3 | 2016 | 4936 | 0.130 |
Why?
|
| Obesity | 3 | 2023 | 12947 | 0.130 |
Why?
|
| Body Weights and Measures | 2 | 2008 | 208 | 0.130 |
Why?
|
| Janus Kinases | 2 | 2018 | 248 | 0.130 |
Why?
|
| Naphthalimides | 1 | 2015 | 22 | 0.130 |
Why?
|
| Antigens, CD | 7 | 2016 | 4003 | 0.120 |
Why?
|
| Body Surface Area | 1 | 2015 | 197 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
| Glycogen Synthase | 1 | 2015 | 62 | 0.120 |
Why?
|
| Hematopoietic Cell Growth Factors | 3 | 2009 | 98 | 0.120 |
Why?
|
| Anemia, Refractory | 2 | 2006 | 17 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 3734 | 0.120 |
Why?
|
| Gout | 1 | 2022 | 621 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2023 | 857 | 0.120 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 370 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 940 | 0.120 |
Why?
|
| Citric Acid Cycle | 1 | 2016 | 231 | 0.120 |
Why?
|
| RNA, Neoplasm | 4 | 2014 | 750 | 0.120 |
Why?
|
| Aging | 3 | 2022 | 8708 | 0.120 |
Why?
|
| Drug Approval | 3 | 2018 | 814 | 0.120 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 271 | 0.120 |
Why?
|
| Interferon-alpha | 4 | 2007 | 921 | 0.120 |
Why?
|
| Interview, Psychological | 1 | 2018 | 809 | 0.120 |
Why?
|
| Creatine Kinase | 1 | 2017 | 685 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 2014 | 111 | 0.120 |
Why?
|
| Eligibility Determination | 1 | 2018 | 421 | 0.120 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 17 | 0.120 |
Why?
|
| Fatigue | 3 | 2017 | 1552 | 0.120 |
Why?
|
| Netherlands | 1 | 2019 | 2221 | 0.120 |
Why?
|
| Cyclin D1 | 1 | 2016 | 451 | 0.120 |
Why?
|
| Colony-Stimulating Factors | 2 | 1992 | 218 | 0.120 |
Why?
|
| Codon | 1 | 2016 | 601 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2020 | 1334 | 0.120 |
Why?
|
| Glycogen | 1 | 2015 | 251 | 0.120 |
Why?
|
| Ikaros Transcription Factor | 1 | 2016 | 232 | 0.120 |
Why?
|
| Hematopoiesis | 5 | 2022 | 2049 | 0.120 |
Why?
|
| Multivariate Analysis | 7 | 2020 | 12059 | 0.120 |
Why?
|
| Canada | 2 | 2019 | 2122 | 0.120 |
Why?
|
| Affect | 2 | 2019 | 1486 | 0.120 |
Why?
|
| Niacinamide | 1 | 2016 | 413 | 0.110 |
Why?
|
| Consensus | 4 | 2023 | 3123 | 0.110 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2015 | 239 | 0.110 |
Why?
|
| Culture | 1 | 2018 | 623 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2013 | 32 | 0.110 |
Why?
|
| Brain Edema | 1 | 2018 | 604 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2013 | 3778 | 0.110 |
Why?
|
| B-Lymphocytes | 4 | 2016 | 4758 | 0.110 |
Why?
|
| History, 20th Century | 3 | 2018 | 2767 | 0.110 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2013 | 47 | 0.110 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 335 | 0.110 |
Why?
|
| Thiazolidines | 1 | 2013 | 69 | 0.110 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 5127 | 0.110 |
Why?
|
| Lymphocyte Depletion | 3 | 2002 | 602 | 0.110 |
Why?
|
| Zebrafish Proteins | 2 | 2011 | 1014 | 0.110 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 1738 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2016 | 507 | 0.110 |
Why?
|
| Cough | 2 | 2015 | 594 | 0.110 |
Why?
|
| Incidence | 10 | 2024 | 21353 | 0.110 |
Why?
|
| Gait | 1 | 2019 | 814 | 0.110 |
Why?
|
| Naphthyridines | 1 | 2014 | 143 | 0.110 |
Why?
|
| Receptor, Notch2 | 1 | 2014 | 87 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2015 | 343 | 0.110 |
Why?
|
| Interleukin-8 | 2 | 1994 | 695 | 0.110 |
Why?
|
| Antigens, CD19 | 2 | 2015 | 424 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 871 | 0.110 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 2 | 2024 | 36 | 0.110 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 452 | 0.110 |
Why?
|
| Tissue Distribution | 3 | 2013 | 2265 | 0.110 |
Why?
|
| Genes, fms | 1 | 1993 | 6 | 0.110 |
Why?
|
| Decision Making | 4 | 2018 | 3929 | 0.110 |
Why?
|
| Child | 17 | 2024 | 80153 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2018 | 1469 | 0.110 |
Why?
|
| Epidemics | 1 | 2019 | 512 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1745 | 0.110 |
Why?
|
| Palliative Care | 5 | 2016 | 3598 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2017 | 716 | 0.110 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2019 | 822 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2016 | 629 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 9000 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2023 | 678 | 0.110 |
Why?
|
| Thiophenes | 1 | 2017 | 569 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 3205 | 0.110 |
Why?
|
| Neuroprotective Agents | 2 | 2019 | 957 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 8 | 2010 | 9177 | 0.110 |
Why?
|
| Pancytopenia | 2 | 2010 | 102 | 0.110 |
Why?
|
| Infection Control | 1 | 2020 | 981 | 0.100 |
Why?
|
| Cell Growth Processes | 2 | 2010 | 384 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1995 | 258 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 1250 | 0.100 |
Why?
|
| HIV Infections | 1 | 2019 | 17351 | 0.100 |
Why?
|
| Hypertension | 2 | 2024 | 8540 | 0.100 |
Why?
|
| Injections, Subcutaneous | 3 | 2010 | 681 | 0.100 |
Why?
|
| Hemorrhage | 4 | 2022 | 3424 | 0.100 |
Why?
|
| Neutrophils | 4 | 2021 | 3767 | 0.100 |
Why?
|
| Gene Expression | 9 | 2015 | 7581 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 2118 | 0.100 |
Why?
|
| Stromal Cells | 3 | 2013 | 1330 | 0.100 |
Why?
|
| RNA Precursors | 1 | 2013 | 212 | 0.100 |
Why?
|
| Leukocyte Count | 4 | 2024 | 1596 | 0.100 |
Why?
|
| Longitudinal Studies | 4 | 2023 | 14605 | 0.100 |
Why?
|
| Biphenyl Compounds | 2 | 2013 | 1007 | 0.100 |
Why?
|
| Societies, Scientific | 1 | 2013 | 222 | 0.100 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 1994 | 662 | 0.100 |
Why?
|
| Arabidopsis Proteins | 1 | 2013 | 264 | 0.100 |
Why?
|
| Genotype | 7 | 2020 | 12990 | 0.100 |
Why?
|
| Carbazoles | 2 | 2011 | 220 | 0.100 |
Why?
|
| Harringtonines | 2 | 2008 | 8 | 0.100 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 421 | 0.100 |
Why?
|
| Anemia, Sideroblastic | 1 | 1992 | 109 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2018 | 1567 | 0.100 |
Why?
|
| Doxorubicin | 3 | 2014 | 2224 | 0.100 |
Why?
|
| Platelet Count | 5 | 2020 | 781 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 2 | 2014 | 934 | 0.100 |
Why?
|
| Interleukin-2 | 2 | 2008 | 1889 | 0.100 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 598 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 1076 | 0.090 |
Why?
|
| Point Mutation | 3 | 2015 | 1595 | 0.090 |
Why?
|
| Uveitis | 1 | 1995 | 395 | 0.090 |
Why?
|
| Bacteremia | 1 | 2018 | 979 | 0.090 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 11121 | 0.090 |
Why?
|
| Metabolome | 1 | 2018 | 989 | 0.090 |
Why?
|
| Mice, SCID | 5 | 2015 | 2626 | 0.090 |
Why?
|
| Whole-Body Irradiation | 2 | 2006 | 433 | 0.090 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2004 | 191 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2022 | 2510 | 0.090 |
Why?
|
| Astrocytes | 1 | 1999 | 1346 | 0.090 |
Why?
|
| Physician Assistants | 1 | 2013 | 191 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2015 | 465 | 0.090 |
Why?
|
| Megakaryocytes | 1 | 2015 | 566 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 988 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 710 | 0.090 |
Why?
|
| Blood Cell Count | 4 | 2004 | 397 | 0.090 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 1990 | 7 | 0.090 |
Why?
|
| Proportional Hazards Models | 8 | 2023 | 12463 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 2057 | 0.090 |
Why?
|
| Cohort Studies | 13 | 2024 | 41487 | 0.090 |
Why?
|
| Phthalazines | 1 | 2013 | 383 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3156 | 0.090 |
Why?
|
| RNA Interference | 4 | 2022 | 2831 | 0.090 |
Why?
|
| Phosphotyrosine | 2 | 2016 | 456 | 0.090 |
Why?
|
| Eyeglasses | 1 | 2011 | 137 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2016 | 1139 | 0.090 |
Why?
|
| Light | 2 | 2008 | 1353 | 0.090 |
Why?
|
| Gene Deletion | 2 | 2016 | 2665 | 0.090 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 15266 | 0.090 |
Why?
|
| Cell Line | 14 | 2018 | 15601 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 754 | 0.090 |
Why?
|
| Mitogens | 2 | 1999 | 230 | 0.090 |
Why?
|
| Neoplasms, Experimental | 4 | 2019 | 1229 | 0.090 |
Why?
|
| Nitric Oxide | 1 | 1999 | 2135 | 0.080 |
Why?
|
| Repressor Proteins | 5 | 2022 | 2986 | 0.080 |
Why?
|
| Mutation, Missense | 4 | 2021 | 2571 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 197 | 0.080 |
Why?
|
| Organ Transplantation | 1 | 2020 | 1157 | 0.080 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2010 | 101 | 0.080 |
Why?
|
| Cells, Cultured | 9 | 2021 | 18965 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 878 | 0.080 |
Why?
|
| Chickens | 1 | 2011 | 859 | 0.080 |
Why?
|
| Feasibility Studies | 4 | 2011 | 5247 | 0.080 |
Why?
|
| Europe | 4 | 2020 | 3422 | 0.080 |
Why?
|
| Genetic Loci | 1 | 2018 | 2632 | 0.080 |
Why?
|
| Indoles | 2 | 2015 | 1833 | 0.080 |
Why?
|
| Carbanilides | 1 | 2008 | 18 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2021 | 2141 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 258 | 0.080 |
Why?
|
| Mucositis | 1 | 2010 | 108 | 0.080 |
Why?
|
| RNA Splicing | 1 | 2013 | 918 | 0.080 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2009 | 135 | 0.080 |
Why?
|
| Zebrafish | 2 | 2011 | 3007 | 0.080 |
Why?
|
| Self-Assessment | 1 | 2011 | 396 | 0.080 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 3358 | 0.080 |
Why?
|
| Topotecan | 1 | 2009 | 132 | 0.080 |
Why?
|
| Patient Admission | 1 | 2016 | 1367 | 0.080 |
Why?
|
| Erythromycin | 1 | 1988 | 115 | 0.080 |
Why?
|
| Cell Fusion | 2 | 2010 | 294 | 0.080 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 18252 | 0.080 |
Why?
|
| Vaccination | 2 | 2021 | 3384 | 0.080 |
Why?
|
| Ocular Hypertension | 1 | 2010 | 209 | 0.080 |
Why?
|
| Gene Silencing | 3 | 2016 | 1509 | 0.080 |
Why?
|
| Research Design | 2 | 2022 | 6180 | 0.080 |
Why?
|
| Lovastatin | 1 | 1988 | 115 | 0.080 |
Why?
|
| Granzymes | 1 | 2010 | 277 | 0.080 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 3 | 1994 | 94 | 0.080 |
Why?
|
| Fibrosis | 1 | 2015 | 2049 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 2015 | 2161 | 0.080 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 384 | 0.080 |
Why?
|
| Spinal Nerves | 1 | 2008 | 91 | 0.080 |
Why?
|
| Research | 1 | 1996 | 1982 | 0.080 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 15842 | 0.080 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2007 | 10 | 0.080 |
Why?
|
| Intensive Care Units | 2 | 2019 | 3745 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2010 | 731 | 0.070 |
Why?
|
| Fatal Outcome | 4 | 2018 | 1834 | 0.070 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2009 | 169 | 0.070 |
Why?
|
| Type C Phospholipases | 1 | 1988 | 287 | 0.070 |
Why?
|
| Antigens, Differentiation | 2 | 2010 | 910 | 0.070 |
Why?
|
| Protons | 1 | 2013 | 1116 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 12974 | 0.070 |
Why?
|
| Body Mass Index | 4 | 2023 | 12953 | 0.070 |
Why?
|
| Cell Lineage | 3 | 2016 | 2555 | 0.070 |
Why?
|
| Rhabdomyolysis | 1 | 1988 | 152 | 0.070 |
Why?
|
| Bone Marrow Examination | 3 | 2016 | 154 | 0.070 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2004 | 556 | 0.070 |
Why?
|
| Erythroid Precursor Cells | 1 | 2008 | 211 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2010 | 3162 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 2759 | 0.070 |
Why?
|
| Crohn Disease | 3 | 1994 | 2279 | 0.070 |
Why?
|
| Photography | 1 | 2010 | 532 | 0.070 |
Why?
|
| alpha Catenin | 1 | 2006 | 37 | 0.070 |
Why?
|
| Nitriles | 2 | 2018 | 971 | 0.070 |
Why?
|
| Dermatomycoses | 1 | 2007 | 48 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2001 | 899 | 0.070 |
Why?
|
| Amino Acid Sequence | 7 | 2016 | 13446 | 0.070 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2008 | 208 | 0.070 |
Why?
|
| Drug Evaluation | 3 | 1993 | 641 | 0.070 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 20098 | 0.070 |
Why?
|
| Chromatin | 3 | 2023 | 2960 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 5440 | 0.070 |
Why?
|
| Antitubercular Agents | 2 | 2014 | 1375 | 0.070 |
Why?
|
| Thionucleotides | 2 | 2021 | 112 | 0.070 |
Why?
|
| Inpatients | 1 | 2018 | 2548 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 1651 | 0.070 |
Why?
|
| Hematologic Agents | 1 | 2006 | 40 | 0.070 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 113 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2220 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2013 | 2057 | 0.070 |
Why?
|
| Torsades de Pointes | 1 | 2007 | 78 | 0.070 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2007 | 164 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 3639 | 0.070 |
Why?
|
| Granulocytes | 1 | 1988 | 551 | 0.070 |
Why?
|
| Genetic Variation | 3 | 2017 | 6567 | 0.060 |
Why?
|
| Stomatitis | 1 | 2008 | 271 | 0.060 |
Why?
|
| Case-Control Studies | 6 | 2018 | 22176 | 0.060 |
Why?
|
| Tyrphostins | 1 | 2005 | 63 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 1995 | 3208 | 0.060 |
Why?
|
| Base Sequence | 8 | 2019 | 12441 | 0.060 |
Why?
|
| Zinc Fingers | 3 | 2004 | 579 | 0.060 |
Why?
|
| Fever | 2 | 2015 | 1618 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 1994 | 1250 | 0.060 |
Why?
|
| Butadienes | 1 | 2005 | 107 | 0.060 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 424 | 0.060 |
Why?
|
| Patient Preference | 1 | 2013 | 924 | 0.060 |
Why?
|
| bcl-Associated Death Protein | 1 | 2005 | 102 | 0.060 |
Why?
|
| Bryostatins | 3 | 1997 | 24 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2010 | 1351 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2019 | 5294 | 0.060 |
Why?
|
| Antigens, CD34 | 3 | 2016 | 658 | 0.060 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 489 | 0.060 |
Why?
|
| Aspergillosis | 1 | 2007 | 242 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 263 | 0.060 |
Why?
|
| Imidazoles | 2 | 2008 | 1180 | 0.060 |
Why?
|
| Unnecessary Procedures | 1 | 2008 | 415 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 636 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 2 | 2010 | 1200 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2020 | 4278 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 2 | 2006 | 565 | 0.060 |
Why?
|
| Tuberculosis | 2 | 2015 | 2017 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 15936 | 0.060 |
Why?
|
| Mice, Nude | 4 | 2016 | 3615 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2009 | 721 | 0.060 |
Why?
|
| Liposomes | 1 | 2008 | 784 | 0.060 |
Why?
|
| North America | 2 | 2023 | 1276 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2005 | 287 | 0.060 |
Why?
|
| Intraocular Pressure | 1 | 2010 | 1294 | 0.060 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2024 | 141 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 3889 | 0.060 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 184 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2004 | 189 | 0.060 |
Why?
|
| Protein Binding | 3 | 2023 | 9351 | 0.060 |
Why?
|
| Observer Variation | 1 | 2010 | 2606 | 0.060 |
Why?
|
| Tissue Donors | 3 | 2009 | 2331 | 0.060 |
Why?
|
| Immunologic Factors | 4 | 2017 | 1589 | 0.060 |
Why?
|
| Myeloablative Agonists | 1 | 2004 | 209 | 0.060 |
Why?
|
| Macrolides | 3 | 1997 | 205 | 0.060 |
Why?
|
| Receptor, Notch1 | 1 | 2006 | 496 | 0.060 |
Why?
|
| Genome, Human | 2 | 2014 | 4425 | 0.050 |
Why?
|
| Leukemia, Monocytic, Acute | 2 | 2007 | 58 | 0.050 |
Why?
|
| Receptors, Notch | 1 | 2008 | 743 | 0.050 |
Why?
|
| Quality of Health Care | 2 | 2016 | 4330 | 0.050 |
Why?
|
| Pyrroles | 2 | 2020 | 1125 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 4740 | 0.050 |
Why?
|
| Diamines | 1 | 2023 | 60 | 0.050 |
Why?
|
| Ricin | 1 | 2003 | 70 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 1990 | 1174 | 0.050 |
Why?
|
| Nervous System Diseases | 2 | 2001 | 1666 | 0.050 |
Why?
|
| Boronic Acids | 3 | 2013 | 915 | 0.050 |
Why?
|
| Terminal Care | 1 | 2015 | 1760 | 0.050 |
Why?
|
| Frail Elderly | 2 | 2019 | 765 | 0.050 |
Why?
|
| Double-Blind Method | 6 | 2001 | 12341 | 0.050 |
Why?
|
| Plasma | 1 | 2006 | 586 | 0.050 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2003 | 105 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 1386 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2020 | 373 | 0.050 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2002 | 7 | 0.050 |
Why?
|
| Immunoblotting | 3 | 2010 | 1646 | 0.050 |
Why?
|
| K562 Cells | 3 | 2010 | 642 | 0.050 |
Why?
|
| Transcription, Genetic | 8 | 2009 | 7594 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3084 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2019 | 375 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2009 | 1242 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3204 | 0.050 |
Why?
|
| Ubiquitination | 2 | 2020 | 1006 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 2016 | 0.050 |
Why?
|
| Quinolines | 1 | 2008 | 764 | 0.050 |
Why?
|
| Cell Count | 2 | 2018 | 1835 | 0.050 |
Why?
|
| Syndrome | 4 | 2013 | 3267 | 0.050 |
Why?
|
| Animals, Newborn | 2 | 2016 | 2678 | 0.050 |
Why?
|
| Thymidine | 1 | 2022 | 299 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 22169 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 3 | 2020 | 3792 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2004 | 345 | 0.050 |
Why?
|
| Patient Participation | 1 | 2011 | 1444 | 0.050 |
Why?
|
| Lymph Nodes | 3 | 2021 | 3466 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 7879 | 0.050 |
Why?
|
| Lighting | 1 | 2003 | 211 | 0.050 |
Why?
|
| Comorbidity | 4 | 2018 | 10508 | 0.050 |
Why?
|
| Geography | 2 | 2020 | 656 | 0.050 |
Why?
|
| Data Collection | 1 | 2011 | 3322 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2018 | 1693 | 0.050 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 12690 | 0.050 |
Why?
|
| Serine | 1 | 2005 | 830 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2017 | 2047 | 0.050 |
Why?
|
| Skin | 1 | 2015 | 4484 | 0.050 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 372 | 0.050 |
Why?
|
| World Health Organization | 2 | 2022 | 1322 | 0.050 |
Why?
|
| Genome | 1 | 2009 | 1740 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2013 | 1246 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2022 | 419 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2024 | 517 | 0.050 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2003 | 220 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 368 | 0.050 |
Why?
|
| Antigen Presentation | 2 | 2021 | 1251 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2008 | 1496 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2022 | 223 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2021 | 91 | 0.050 |
Why?
|
| Cell Death | 2 | 2013 | 1678 | 0.050 |
Why?
|
| Work | 1 | 2002 | 195 | 0.050 |
Why?
|
| Cytosine | 1 | 2022 | 211 | 0.050 |
Why?
|
| Surgical Staplers | 1 | 1980 | 34 | 0.050 |
Why?
|
| Cytokines | 4 | 2021 | 7396 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 1994 | 4352 | 0.050 |
Why?
|
| Pennsylvania | 1 | 2002 | 613 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2002 | 367 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 1089 | 0.050 |
Why?
|
| Histocompatibility | 1 | 2002 | 317 | 0.050 |
Why?
|
| HLA Antigens | 2 | 2019 | 1328 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 1705 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1612 | 0.040 |
Why?
|
| Drug Monitoring | 2 | 2006 | 962 | 0.040 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2023 | 284 | 0.040 |
Why?
|
| Growth Substances | 1 | 2002 | 768 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2011 | 3612 | 0.040 |
Why?
|
| Clone Cells | 2 | 2016 | 1659 | 0.040 |
Why?
|
| Hyperbilirubinemia | 1 | 2020 | 74 | 0.040 |
Why?
|
| Creatinine | 2 | 2018 | 1899 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 2421 | 0.040 |
Why?
|
| Visual Acuity | 2 | 2003 | 2672 | 0.040 |
Why?
|
| Perception | 2 | 2018 | 1197 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2023 | 576 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2021 | 14414 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2022 | 306 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2021 | 306 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 1 | 2021 | 510 | 0.040 |
Why?
|
| Pneumonia | 3 | 1999 | 2143 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2017 | 1880 | 0.040 |
Why?
|
| Neurons | 1 | 1999 | 9463 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 2200 | 0.040 |
Why?
|
| Glutathione Disulfide | 1 | 1999 | 33 | 0.040 |
Why?
|
| Arachidonic Acids | 2 | 1990 | 294 | 0.040 |
Why?
|
| Molecular Sequence Data | 5 | 2005 | 17635 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 1999 | 56 | 0.040 |
Why?
|
| Standard of Care | 1 | 2023 | 551 | 0.040 |
Why?
|
| Lactams | 1 | 1979 | 156 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 1999 | 148 | 0.040 |
Why?
|
| Massachusetts | 2 | 2024 | 8830 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2018 | 95 | 0.040 |
Why?
|
| Portacaval Shunt, Surgical | 5 | 1985 | 46 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 1036 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2016 | 42230 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 1486 | 0.040 |
Why?
|
| Leukemia, Experimental | 2 | 2016 | 225 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 1519 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 413 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2004 | 3087 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2004 | 824 | 0.040 |
Why?
|
| Bartter Syndrome | 1 | 1997 | 23 | 0.040 |
Why?
|
| Bone Marrow Purging | 2 | 1997 | 108 | 0.040 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 26125 | 0.040 |
Why?
|
| Drug Resistance | 3 | 2005 | 1596 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3877 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 350 | 0.040 |
Why?
|
| Medicare | 1 | 2016 | 6770 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2020 | 364 | 0.040 |
Why?
|
| Nootropic Agents | 1 | 1998 | 157 | 0.040 |
Why?
|
| Transplantation Chimera | 2 | 2014 | 594 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2020 | 297 | 0.040 |
Why?
|
| Sequence Deletion | 3 | 2009 | 1494 | 0.040 |
Why?
|
| Cell Division | 3 | 2004 | 4465 | 0.040 |
Why?
|
| Furans | 2 | 2011 | 202 | 0.040 |
Why?
|
| Immunity, Innate | 2 | 2021 | 3065 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2001 | 283 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 712 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 522 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2018 | 188 | 0.040 |
Why?
|
| Hydrolases | 1 | 2018 | 147 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2022 | 526 | 0.040 |
Why?
|
| Megacolon, Toxic | 1 | 1977 | 8 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2018 | 411 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2006 | 3905 | 0.040 |
Why?
|
| Phosphorus | 1 | 2018 | 336 | 0.040 |
Why?
|
| Mammals | 1 | 2023 | 1132 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 1667 | 0.040 |
Why?
|
| Endocytosis | 1 | 2021 | 957 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2021 | 587 | 0.030 |
Why?
|
| Embryo, Nonmammalian | 2 | 2011 | 906 | 0.030 |
Why?
|
| Dogs | 4 | 2020 | 3839 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2021 | 835 | 0.030 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2016 | 66 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2022 | 999 | 0.030 |
Why?
|
| Off-Label Use | 1 | 2018 | 185 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 2645 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3810 | 0.030 |
Why?
|
| Kinetics | 3 | 2002 | 6374 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 783 | 0.030 |
Why?
|
| Blood Cells | 2 | 2013 | 305 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2020 | 846 | 0.030 |
Why?
|
| Chloride Channels | 1 | 1997 | 221 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2022 | 3080 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 1990 | 3979 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2022 | 6240 | 0.030 |
Why?
|
| Cell Communication | 2 | 2013 | 1657 | 0.030 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2016 | 103 | 0.030 |
Why?
|
| Benzylamines | 1 | 2017 | 247 | 0.030 |
Why?
|
| Dipeptides | 1 | 2018 | 391 | 0.030 |
Why?
|
| Aphakia | 1 | 1996 | 26 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2016 | 310 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2016 | 4124 | 0.030 |
Why?
|
| Proteomics | 1 | 2009 | 3849 | 0.030 |
Why?
|
| Corneal Opacity | 1 | 1996 | 47 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2022 | 5079 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 1560 | 0.030 |
Why?
|
| Gastrectomy | 1 | 1980 | 672 | 0.030 |
Why?
|
| Coloboma | 1 | 1996 | 59 | 0.030 |
Why?
|
| SEER Program | 1 | 2020 | 1450 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2018 | 2496 | 0.030 |
Why?
|
| Hyperuricemia | 1 | 2018 | 222 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 1993 | 186 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 1125 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 4915 | 0.030 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 21 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2003 | 954 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2023 | 1033 | 0.030 |
Why?
|
| Prevalence | 3 | 2018 | 15732 | 0.030 |
Why?
|
| Sample Size | 1 | 2018 | 841 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 254 | 0.030 |
Why?
|
| Colectomy | 2 | 1978 | 688 | 0.030 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2016 | 263 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1999 | 1848 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2023 | 8631 | 0.030 |
Why?
|
| Anterior Eye Segment | 1 | 1996 | 143 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2015 | 200 | 0.030 |
Why?
|
| Mediastinal Diseases | 1 | 2015 | 91 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 496 | 0.030 |
Why?
|
| DNA Primers | 3 | 2006 | 2819 | 0.030 |
Why?
|
| Ifosfamide | 1 | 1995 | 232 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2015 | 350 | 0.030 |
Why?
|
| RNA | 2 | 2019 | 2726 | 0.030 |
Why?
|
| Self Report | 2 | 2017 | 3724 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2022 | 2330 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 1998 | 637 | 0.030 |
Why?
|
| Models, Economic | 1 | 1998 | 716 | 0.030 |
Why?
|
| International Agencies | 1 | 2015 | 243 | 0.030 |
Why?
|
| Esophagus | 1 | 1980 | 1033 | 0.030 |
Why?
|
| Hyponatremia | 1 | 2017 | 279 | 0.030 |
Why?
|
| Anterior Chamber | 1 | 1995 | 194 | 0.030 |
Why?
|
| Femoral Artery | 1 | 1998 | 826 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 184 | 0.030 |
Why?
|
| Life Tables | 3 | 2002 | 364 | 0.030 |
Why?
|
| Binding Sites | 1 | 2023 | 6055 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 1702 | 0.030 |
Why?
|
| Pimozide | 1 | 2013 | 21 | 0.030 |
Why?
|
| Ethambutol | 1 | 1994 | 59 | 0.030 |
Why?
|
| Random Allocation | 3 | 2016 | 2395 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1999 | 1687 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 1934 | 0.030 |
Why?
|
| Cell Shape | 1 | 2015 | 371 | 0.030 |
Why?
|
| Pentoxifylline | 1 | 1994 | 53 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 638 | 0.030 |
Why?
|
| Hydroxyurea | 1 | 1995 | 284 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 4580 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1787 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 1745 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2014 | 210 | 0.030 |
Why?
|
| Receptors, CXCR | 1 | 2013 | 52 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 846 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 712 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 1975 | 556 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 5492 | 0.030 |
Why?
|
| Morbidity | 1 | 2019 | 1750 | 0.030 |
Why?
|
| Necrosis | 2 | 2011 | 1611 | 0.030 |
Why?
|
| Biopsy | 2 | 2015 | 6766 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 3164 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3579 | 0.030 |
Why?
|
| Nitrophenols | 1 | 2013 | 169 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3688 | 0.030 |
Why?
|
| Cognition | 1 | 2011 | 6990 | 0.030 |
Why?
|
| Eye Neoplasms | 1 | 1975 | 307 | 0.030 |
Why?
|
| Immunotoxins | 2 | 1994 | 175 | 0.030 |
Why?
|
| Carboxylesterase | 1 | 1993 | 31 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2024 | 7856 | 0.030 |
Why?
|
| Skin Tests | 1 | 2015 | 637 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2018 | 1699 | 0.030 |
Why?
|
| Rats | 2 | 2020 | 23742 | 0.030 |
Why?
|
| Camptothecin | 1 | 1996 | 591 | 0.030 |
Why?
|
| Forecasting | 1 | 2002 | 2928 | 0.030 |
Why?
|
| Multiple Sclerosis | 2 | 2002 | 3220 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2013 | 146 | 0.030 |
Why?
|
| Reference Values | 1 | 2020 | 4920 | 0.030 |
Why?
|
| Infertility, Male | 1 | 1996 | 395 | 0.030 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1993 | 99 | 0.030 |
Why?
|
| Vitreous Body | 1 | 1995 | 399 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 1980 | 1116 | 0.030 |
Why?
|
| Electrons | 1 | 2014 | 265 | 0.030 |
Why?
|
| beta Catenin | 1 | 2018 | 1040 | 0.030 |
Why?
|
| Retinal Neovascularization | 1 | 1996 | 288 | 0.030 |
Why?
|
| Benchmarking | 1 | 2019 | 1045 | 0.030 |
Why?
|
| Hormones | 1 | 2016 | 869 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 2850 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2017 | 839 | 0.030 |
Why?
|
| Peer Group | 1 | 2018 | 692 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2014 | 595 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 1992 | 127 | 0.030 |
Why?
|
| Picibanil | 1 | 1992 | 10 | 0.030 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2012 | 94 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2018 | 3461 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 789 | 0.030 |
Why?
|
| Isoniazid | 1 | 1994 | 283 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 829 | 0.030 |
Why?
|
| Overweight | 1 | 2023 | 2417 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 372 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 317 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 3076 | 0.020 |
Why?
|
| Students | 1 | 2002 | 1741 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2015 | 733 | 0.020 |
Why?
|
| Rifampin | 1 | 1994 | 339 | 0.020 |
Why?
|
| Carboplatin | 1 | 1995 | 794 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 4249 | 0.020 |
Why?
|
| Cranial Irradiation | 2 | 2010 | 390 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 1062 | 0.020 |
Why?
|
| Registries | 3 | 2020 | 8224 | 0.020 |
Why?
|
| Hyperplasia | 1 | 1995 | 1152 | 0.020 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 84 | 0.020 |
Why?
|
| DNA Repair | 1 | 2021 | 2045 | 0.020 |
Why?
|
| Ligands | 1 | 2018 | 3272 | 0.020 |
Why?
|
| Peripheral Nervous System | 1 | 2012 | 151 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2014 | 749 | 0.020 |
Why?
|
| Cadherins | 1 | 2016 | 903 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 982 | 0.020 |
Why?
|
| Exons | 3 | 2009 | 2391 | 0.020 |
Why?
|
| Heparin | 2 | 1990 | 1634 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2016 | 1022 | 0.020 |
Why?
|
| Arthralgia | 1 | 2015 | 461 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 796 | 0.020 |
Why?
|
| Molecular Sequence Annotation | 1 | 2013 | 522 | 0.020 |
Why?
|
| Depression | 2 | 2023 | 8124 | 0.020 |
Why?
|
| Models, Molecular | 2 | 2016 | 5439 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2011 | 166 | 0.020 |
Why?
|
| Acetamides | 1 | 1992 | 256 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 2735 | 0.020 |
Why?
|
| Spleen | 2 | 2003 | 2295 | 0.020 |
Why?
|
| Glycolysis | 1 | 2015 | 835 | 0.020 |
Why?
|
| Inverted Repeat Sequences | 1 | 2010 | 60 | 0.020 |
Why?
|
| Graft Survival | 4 | 2006 | 3819 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1992 | 416 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2006 | 3429 | 0.020 |
Why?
|
| Genes, myc | 1 | 1991 | 390 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2011 | 295 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2002 | 6343 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2015 | 1967 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 615 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 3879 | 0.020 |
Why?
|
| Luteal Cells | 1 | 1990 | 19 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2004 | 257 | 0.020 |
Why?
|
| Trans-Activators | 2 | 2013 | 2856 | 0.020 |
Why?
|
| Health Resources | 1 | 2016 | 935 | 0.020 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 1990 | 28 | 0.020 |
Why?
|
| Lead | 1 | 1996 | 879 | 0.020 |
Why?
|
| Pandemics | 2 | 2020 | 8654 | 0.020 |
Why?
|
| ras Proteins | 1 | 2015 | 1054 | 0.020 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2010 | 71 | 0.020 |
Why?
|
| Pregnancy | 3 | 2016 | 29874 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1999 | 918 | 0.020 |
Why?
|
| Liver | 3 | 2003 | 7529 | 0.020 |
Why?
|
| Length of Stay | 3 | 2013 | 6425 | 0.020 |
Why?
|
| Corpus Luteum | 1 | 1990 | 81 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 1990 | 116 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2020 | 2479 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2011 | 260 | 0.020 |
Why?
|
| Myelopoiesis | 1 | 2010 | 134 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2010 | 36426 | 0.020 |
Why?
|
| Classification | 1 | 2010 | 127 | 0.020 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 3249 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 473 | 0.020 |
Why?
|
| Permeability | 1 | 2011 | 723 | 0.020 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2010 | 224 | 0.020 |
Why?
|
| Cotinine | 1 | 1990 | 206 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2023 | 5496 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1893 | 0.020 |
Why?
|
| Cell Movement | 1 | 2021 | 5203 | 0.020 |
Why?
|
| Esophageal and Gastric Varices | 3 | 1985 | 208 | 0.020 |
Why?
|
| Thalassemia | 1 | 2009 | 267 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2016 | 2919 | 0.020 |
Why?
|
| Boston | 2 | 2019 | 9326 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2022 | 3600 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1992 | 864 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 2 | 2008 | 7407 | 0.020 |
Why?
|
| Autoantigens | 1 | 1993 | 891 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1997 | 1802 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 727 | 0.020 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 1998 | 1228 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2010 | 361 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 1641 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 9031 | 0.020 |
Why?
|
| Radiography | 3 | 2015 | 6965 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2010 | 418 | 0.020 |
Why?
|
| Carmustine | 1 | 2008 | 138 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4369 | 0.020 |
Why?
|
| Diphtheria Toxin | 1 | 1989 | 253 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2012 | 828 | 0.020 |
Why?
|
| Splenectomy | 1 | 1990 | 391 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 1988 | 176 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 1996 | 1423 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2012 | 1435 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 1922 | 0.020 |
Why?
|
| Autophagy | 1 | 2016 | 1326 | 0.020 |
Why?
|
| Cornea | 1 | 1996 | 1333 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 265 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1990 | 369 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 1756 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2014 | 1132 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2009 | 285 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 2449 | 0.020 |
Why?
|
| Cell Membrane | 2 | 2016 | 3688 | 0.020 |
Why?
|
| Cell Size | 1 | 2009 | 624 | 0.020 |
Why?
|
| PubMed | 1 | 2008 | 129 | 0.020 |
Why?
|
| Donor Selection | 1 | 2009 | 232 | 0.020 |
Why?
|
| Oxazines | 1 | 2009 | 350 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 1900 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1995 | 1378 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 1990 | 820 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2010 | 888 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2009 | 392 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2008 | 255 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 453 | 0.020 |
Why?
|
| Blood Coagulation | 2 | 1990 | 1154 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1990 | 416 | 0.020 |
Why?
|
| Melphalan | 1 | 2008 | 420 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 2707 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 2243 | 0.020 |
Why?
|
| Angiotensin II | 1 | 1990 | 849 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 2020 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9539 | 0.020 |
Why?
|
| Choline | 1 | 1988 | 515 | 0.020 |
Why?
|
| Sacrum | 1 | 2008 | 276 | 0.020 |
Why?
|
| Morpholines | 1 | 2009 | 581 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 1989 | 687 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 1055 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 2006 | 86 | 0.020 |
Why?
|
| Health Personnel | 1 | 2020 | 3335 | 0.020 |
Why?
|
| Pathology, Clinical | 1 | 2010 | 376 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1862 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 1792 | 0.020 |
Why?
|
| Monitoring, Physiologic | 2 | 2006 | 1779 | 0.020 |
Why?
|
| Gene Library | 1 | 2008 | 1059 | 0.020 |
Why?
|
| Cross-Over Studies | 2 | 2002 | 2078 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 1996 | 1813 | 0.020 |
Why?
|
| Prednisolone | 2 | 1999 | 326 | 0.020 |
Why?
|
| Models, Biological | 2 | 2014 | 9469 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 1720 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 11076 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2009 | 787 | 0.020 |
Why?
|
| Homeostasis | 1 | 2016 | 3323 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2011 | 1187 | 0.020 |
Why?
|
| Splenorenal Shunt, Surgical | 1 | 1985 | 14 | 0.020 |
Why?
|
| Gene Expression Regulation | 3 | 1994 | 11903 | 0.020 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1985 | 39 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2010 | 983 | 0.020 |
Why?
|
| Aziridines | 1 | 2004 | 21 | 0.020 |
Why?
|
| Calcium | 1 | 2018 | 5722 | 0.020 |
Why?
|
| Mortality | 1 | 2016 | 2901 | 0.020 |
Why?
|
| Tyrosine | 1 | 2009 | 1440 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 5789 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 2231 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1987 | 559 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1379 | 0.010 |
Why?
|
| Blood Coagulation Disorders | 1 | 1988 | 350 | 0.010 |
Why?
|
| Protein Transport | 1 | 2010 | 1967 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 1229 | 0.010 |
Why?
|
| Colitis, Ulcerative | 1 | 1977 | 1922 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 719 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 2004 | 192 | 0.010 |
Why?
|
| Milk Proteins | 1 | 2005 | 163 | 0.010 |
Why?
|
| Risk | 3 | 2010 | 9610 | 0.010 |
Why?
|
| Computational Biology | 1 | 2016 | 3518 | 0.010 |
Why?
|
| Benzoquinones | 1 | 2004 | 198 | 0.010 |
Why?
|
| Homozygote | 1 | 2009 | 1776 | 0.010 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1990 | 819 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1988 | 1416 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2007 | 569 | 0.010 |
Why?
|
| Hydrogen Bonding | 1 | 2004 | 291 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1990 | 782 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 1990 | 867 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2016 | 9646 | 0.010 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2012 | 916 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 4414 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 2319 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 2 | 1983 | 1277 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 931 | 0.010 |
Why?
|
| Genes, abl | 1 | 2003 | 69 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 1188 | 0.010 |
Why?
|
| Splenic Vein | 2 | 1980 | 30 | 0.010 |
Why?
|
| Phenoxybenzamine | 1 | 1982 | 53 | 0.010 |
Why?
|
| Decision Trees | 1 | 2005 | 504 | 0.010 |
Why?
|
| Photoperiod | 1 | 2003 | 139 | 0.010 |
Why?
|
| ADP Ribose Transferases | 1 | 1983 | 90 | 0.010 |
Why?
|
| Pancreatic Elastase | 1 | 1983 | 127 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 4174 | 0.010 |
Why?
|
| Exotoxins | 1 | 1983 | 121 | 0.010 |
Why?
|
| Informed Consent | 1 | 2009 | 1008 | 0.010 |
Why?
|
| Renal Veins | 2 | 1980 | 102 | 0.010 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 1982 | 81 | 0.010 |
Why?
|
| Finland | 1 | 2003 | 607 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 814 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3514 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 1349 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 1505 | 0.010 |
Why?
|
| Guinea Pigs | 2 | 1983 | 1310 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 679 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2015 | 3537 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2008 | 2601 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2005 | 964 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 3416 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1993 | 3312 | 0.010 |
Why?
|
| Memory | 1 | 2011 | 2188 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 2065 | 0.010 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 961 | 0.010 |
Why?
|
| Blotting, Northern | 2 | 1993 | 1545 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2008 | 1608 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2009 | 1858 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 850 | 0.010 |
Why?
|
| Attention | 1 | 2011 | 2396 | 0.010 |
Why?
|
| Ticarcillin | 1 | 1979 | 8 | 0.010 |
Why?
|
| Carbenicillin | 1 | 1979 | 12 | 0.010 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 675 | 0.010 |
Why?
|
| Prostate | 1 | 1988 | 1770 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2001 | 310 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2011 | 3113 | 0.010 |
Why?
|
| Tobramycin | 1 | 1979 | 65 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 1991 | 286 | 0.010 |
Why?
|
| Pedigree | 3 | 1997 | 4542 | 0.010 |
Why?
|
| DNA Damage | 1 | 2009 | 2446 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 4174 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1999 | 42 | 0.010 |
Why?
|
| Selegiline | 1 | 1998 | 32 | 0.010 |
Why?
|
| Virulence Factors | 1 | 1983 | 513 | 0.010 |
Why?
|
| Lung | 2 | 2015 | 10000 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2013 | 3270 | 0.010 |
Why?
|
| Calcitriol | 2 | 1991 | 296 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 6485 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2003 | 1336 | 0.010 |
Why?
|
| Atrophy | 1 | 2004 | 1633 | 0.010 |
Why?
|
| Gentamicins | 1 | 1979 | 243 | 0.010 |
Why?
|
| Melanoma | 2 | 1989 | 5709 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 5774 | 0.010 |
Why?
|
| Histones | 1 | 2009 | 2580 | 0.010 |
Why?
|
| Filgrastim | 1 | 1998 | 132 | 0.010 |
Why?
|
| Fibronectins | 1 | 1982 | 723 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2005 | 1475 | 0.010 |
Why?
|
| Indans | 1 | 1998 | 92 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 1974 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1990 | 2223 | 0.010 |
Why?
|
| Loop of Henle | 1 | 1997 | 38 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 7045 | 0.010 |
Why?
|
| Brain Diseases | 2 | 1985 | 1545 | 0.010 |
Why?
|
| Gingival Hyperplasia | 1 | 1997 | 19 | 0.010 |
Why?
|
| Crossing Over, Genetic | 1 | 1997 | 92 | 0.010 |
Why?
|
| Infant | 2 | 2016 | 36192 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 1998 | 8599 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 1983 | 931 | 0.010 |
Why?
|
| Reference Standards | 1 | 2000 | 1003 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1999 | 441 | 0.010 |
Why?
|
| Echinococcosis, Hepatic | 1 | 1976 | 24 | 0.010 |
Why?
|
| Carcinoma | 1 | 1988 | 2330 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 14666 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1996 | 106 | 0.010 |
Why?
|
| Birth Certificates | 1 | 1996 | 71 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1985 | 1298 | 0.010 |
Why?
|
| Terminology as Topic | 2 | 2001 | 1530 | 0.010 |
Why?
|
| Ileostomy | 1 | 1977 | 121 | 0.010 |
Why?
|
| Reoperation | 1 | 2006 | 4303 | 0.010 |
Why?
|
| Ileum | 1 | 1978 | 557 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 7827 | 0.010 |
Why?
|
| Physicians | 1 | 2014 | 4591 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 1844 | 0.010 |
Why?
|
| Postoperative Complications | 5 | 1990 | 15631 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1999 | 617 | 0.010 |
Why?
|
| Thioguanine | 1 | 1995 | 45 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1976 | 384 | 0.010 |
Why?
|
| Comprehensive Health Care | 1 | 1976 | 123 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1997 | 638 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 1964 | 0.010 |
Why?
|
| Birth Rate | 1 | 1996 | 168 | 0.010 |
Why?
|
| Introns | 1 | 1997 | 981 | 0.010 |
Why?
|
| Ethers, Cyclic | 1 | 1994 | 32 | 0.010 |
Why?
|
| Military Personnel | 1 | 2003 | 1246 | 0.010 |
Why?
|
| Marriage | 1 | 1976 | 351 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 1994 | 67 | 0.010 |
Why?
|
| Genes, jun | 1 | 1994 | 69 | 0.010 |
Why?
|
| Placebos | 1 | 1998 | 1667 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2003 | 2547 | 0.010 |
Why?
|
| Radioimmunotherapy | 1 | 1994 | 91 | 0.010 |
Why?
|
| Occupations | 1 | 1996 | 515 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1993 | 100 | 0.010 |
Why?
|
| New York | 1 | 1996 | 874 | 0.010 |
Why?
|
| Rectum | 1 | 1978 | 892 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 3395 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1994 | 205 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 6228 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1979 | 1937 | 0.010 |
Why?
|
| Smoking | 1 | 1990 | 9053 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 3442 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 1993 | 186 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1999 | 3093 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 9318 | 0.010 |
Why?
|
| Pyrimidine Nucleosides | 1 | 1991 | 7 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 3808 | 0.010 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1991 | 56 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1997 | 2341 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1976 | 592 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1993 | 1085 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1993 | 436 | 0.010 |
Why?
|
| Hamartoma | 1 | 1973 | 235 | 0.010 |
Why?
|
| Administration, Intravesical | 1 | 1990 | 92 | 0.010 |
Why?
|
| Bronchial Arteries | 1 | 1970 | 21 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1994 | 736 | 0.010 |
Why?
|
| Alkaloids | 1 | 1991 | 192 | 0.010 |
Why?
|
| Saralasin | 1 | 1990 | 34 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1991 | 251 | 0.010 |
Why?
|
| Emergencies | 1 | 1977 | 1217 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 1980 | 1654 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1980 | 1459 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 1975 | 1059 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1990 | 343 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 1998 | 1489 | 0.010 |
Why?
|
| Melanoma-Specific Antigens | 1 | 1989 | 74 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1989 | 189 | 0.010 |
Why?
|
| Genes | 1 | 1993 | 1823 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1980 | 1935 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1997 | 4615 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1976 | 1499 | 0.010 |
Why?
|
| Replantation | 1 | 1970 | 145 | 0.010 |
Why?
|
| Gastric Juice | 1 | 1968 | 59 | 0.000 |
Why?
|
| Educational Status | 1 | 1976 | 2522 | 0.000 |
Why?
|
| Transferrin | 1 | 1989 | 283 | 0.000 |
Why?
|
| Hydrolysis | 1 | 1989 | 664 | 0.000 |
Why?
|
| Electrocardiography | 1 | 2001 | 6377 | 0.000 |
Why?
|
| Cystoscopy | 1 | 1988 | 131 | 0.000 |
Why?
|
| Palpation | 1 | 1988 | 166 | 0.000 |
Why?
|
| Sarcoma, Experimental | 1 | 1987 | 117 | 0.000 |
Why?
|
| Catalysis | 1 | 1989 | 774 | 0.000 |
Why?
|
| Pulmonary Circulation | 1 | 1970 | 737 | 0.000 |
Why?
|
| Arachidonic Acid | 1 | 1989 | 427 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 1302 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1989 | 2186 | 0.000 |
Why?
|
| Plasmacytoma | 1 | 1987 | 171 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1987 | 436 | 0.000 |
Why?
|
| Preleukemia | 1 | 1986 | 34 | 0.000 |
Why?
|
| Epitopes | 1 | 1993 | 2503 | 0.000 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1982 | 3763 | 0.000 |
Why?
|
| Mice, Inbred DBA | 1 | 1987 | 621 | 0.000 |
Why?
|
| Actins | 1 | 1993 | 2050 | 0.000 |
Why?
|
| Progesterone | 1 | 1990 | 742 | 0.000 |
Why?
|
| Transforming Growth Factor beta | 1 | 1993 | 1961 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1988 | 11118 | 0.000 |
Why?
|
| Adenocarcinoma | 2 | 1980 | 6346 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1987 | 1762 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1980 | 4026 | 0.000 |
Why?
|
| Gastric Mucosa | 1 | 1967 | 604 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1989 | 2469 | 0.000 |
Why?
|
| Melanoma, Experimental | 1 | 1987 | 560 | 0.000 |
Why?
|
| Cattle | 1 | 1990 | 3849 | 0.000 |
Why?
|
| Veins | 1 | 1988 | 768 | 0.000 |
Why?
|
| Species Specificity | 1 | 1987 | 2414 | 0.000 |
Why?
|
| Brain | 2 | 2004 | 27112 | 0.000 |
Why?
|
| Chemical Precipitation | 1 | 1982 | 175 | 0.000 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1982 | 91 | 0.000 |
Why?
|
| Urodynamics | 1 | 1982 | 346 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1973 | 2298 | 0.000 |
Why?
|
| Urethra | 1 | 1982 | 405 | 0.000 |
Why?
|
| Synovial Fluid | 1 | 1982 | 393 | 0.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1990 | 1405 | 0.000 |
Why?
|
| Pressure | 1 | 1982 | 1154 | 0.000 |
Why?
|
| Virulence | 1 | 1983 | 1303 | 0.000 |
Why?
|
| Ontario | 1 | 1980 | 398 | 0.000 |
Why?
|
| Insulin | 1 | 1993 | 6596 | 0.000 |
Why?
|
| Cold Temperature | 1 | 1982 | 785 | 0.000 |
Why?
|
| Prostatic Hyperplasia | 1 | 1982 | 521 | 0.000 |
Why?
|
| Mesenteric Veins | 1 | 1978 | 86 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1973 | 4320 | 0.000 |
Why?
|
| Methods | 1 | 1976 | 1067 | 0.000 |
Why?
|
| Rupture, Spontaneous | 1 | 1976 | 362 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1996 | 26198 | 0.000 |
Why?
|
| Suction | 1 | 1976 | 266 | 0.000 |
Why?
|
| Vena Cava, Inferior | 1 | 1978 | 458 | 0.000 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1978 | 952 | 0.000 |
Why?
|
| Mitochondria, Liver | 1 | 1973 | 190 | 0.000 |
Why?
|
| Suture Techniques | 1 | 1976 | 769 | 0.000 |
Why?
|
| Drainage | 1 | 1976 | 1157 | 0.000 |
Why?
|
| Ethanol | 1 | 1976 | 1324 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1973 | 2561 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1973 | 1134 | 0.000 |
Why?
|
| Wound Healing | 1 | 1976 | 2805 | 0.000 |
Why?
|
| Angiography | 1 | 1970 | 1595 | 0.000 |
Why?
|
| Portal Vein | 1 | 1967 | 431 | 0.000 |
Why?
|
| Bronchoscopy | 1 | 1970 | 909 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1987 | 13380 | 0.000 |
Why?
|